Financing ·
Conexeu Sciences Inc. filed a Form 8-K to disclose unregistered sales of equity securities that exceeded 5% of its…
CNXUConexeu Sciences Inc.
Conexeu Sciences Inc. filed a Form 8-K to disclose unregistered sales of equity securities that exceeded 5% of its outstanding shares between June 18 and September 4, 2026. The company issued an aggregate of 1,448,368 common stock shares and 202,500 warrants. Key transactions include the issuance of 762,608 shares for $1,753,998.40 via warrant exercises on September 4, and 202,500 warrants plus 202,500 shares for approximately $162,202.50 on June 18. Additional issuances involved consulting and board agreements with share counts ranging from 1,601 to 70,000 at deemed prices between $2.30 and $13.96. Conexeu Sciences Inc. operates in the biotechnology industry, focusing on drug discovery.